RESUMO
Breast cancers are known to frequently [over] express several well-characterized tumor-associated antigens [TAAs] such as members of the MAGE-family. In the present study we are aiming to evaluate MAGE-1 expression in breast infiltrating duct carcinoma [NOS] in relation to some other known prognostic factors. We will compare this with MAGE-1 expression in some of the benign breast tumors and tumor-like lesions. We are also aiming to study the relation between MAGE-1 expression and lymphocytic response specifically CD8+ T lymphocytes as a hope for further breast cancer immunotherapy. After obtaining informed consent, tissues were obtained from patients undergoing breast lumpectomy or mastectomy. 132 patients of breast infiltrating duct carcinoma [IDC] [NOS] and 65 benign breast lesions were enrolled in this study. The cases were evaluated clinically by the surgeon and physician and any other information was added from the accompanying clinical data. All cases were studied by the histopathologist and immunostain was done for MAGE-1 and CDS. The malignant cases were additionally stained by estrogjenj-eceptors, progesterone receptors and Her-2 as a prognostic markers. The results were statistically studied and tabulated. In the present study we classified the patients into two groups. Group I: Include patients with breast carcinomas of IDC [NOS] type and group II: Include patients with benign breast lesions. The total number of cases was 197, 35 were males while 162 were females. Age ranged between 18-88.132 of the cases were with IDC [NOS] and 65 were with benign breast lesions. There was a significant difference in V1AGE-1 expression between the both groups, it was more expressed in group I and there was a highly significant relation between MAGE-1 expression in IDC [NOS] and the score of CD8+lymphocytes. On the other hand the relation between MAGE-1 and CD8+ lymphocytes was not significant in group II. In fibrocytic disease [FCD], MAGE was +2 in most of FCD cases and CD8+ lymphocytes scored +4 in four cases, but still the relation between the both variables non significant. We have demonstrated in the present study that MAGE-1 is expressed in some of benign breast lesions and at a high proportion in high-grade, hormone receptor-negative breast cancer, suggesting that MAGE-1 could be an indicator of aggressive diseases and can be a promising tumor antigen for immunotherapy of breast cancer with poor prognosis. On the other hand we suggest further studies to evaluate the rule of MAGE-1 vaccine in benign breast lesions as a preventive therapy